Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mental status changes19.07.01.0010.008752%Not Available
Musculoskeletal disorder15.03.05.0250.003376%Not Available
Urosepsis20.08.02.002; 11.01.11.005--Not Available
Axillary pain08.01.08.0150.000530%Not Available
Deafness unilateral04.02.01.0110.000482%Not Available
Hypoacusis04.02.01.0060.013285%
Onychoclasis23.02.05.0050.001832%Not Available
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.0130.009958%Not Available
Performance status decreased08.01.03.0420.001953%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.153902%Not Available
Neutropenic sepsis11.01.11.006; 01.02.03.007--Not Available
Allergic sinusitis22.04.06.003; 10.01.03.0210.000820%Not Available
Lip blister23.03.01.016; 07.05.01.0070.001350%Not Available
Precancerous skin lesion23.01.06.0040.000651%Not Available
General physical health deterioration08.01.03.018--Not Available
Muscle fatigue15.05.03.0060.001230%Not Available
Urethral haemorrhage24.07.03.006; 20.07.01.0030.000241%Not Available
Muscle tightness15.05.03.0070.004340%Not Available
Balance disorder17.02.02.007; 08.01.03.0810.038409%Not Available
Cardiac death08.04.01.007; 02.03.04.0150.000241%Not Available
Skin tightness23.03.03.0180.000820%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.009138%
Deep vein thrombosis24.01.02.0030.021073%Not Available
Malignant neoplasm progression16.16.01.005--Not Available
Prostatomegaly21.04.01.0020.002990%Not Available
Tongue eruption07.14.02.0150.000820%Not Available
Ear congestion04.03.01.0100.000530%Not Available
Ear discomfort04.03.01.0050.002001%Not Available
Ear pruritus04.03.01.0110.001881%Not Available
Eye oedema06.08.03.0130.000651%Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 16 Pages